XENOTHERA, a French biotech company funded by the EIC, has publicly confirmed that its anti-Covid-19 treatment, named XAV-19, effectively treats several COVID-19 variants. The XAV-19 treatment is being tested in a clinical trial implemented in around 20 French hospitals.